



GKB Ophthalmics Ltd.

16-A, Tivim Industrial Estate, Mapusa, Goa 403 526 (INDIA)
CIN.: L26109GA1981PLC000469

Tel. : (91 832) 6714444
E-mail : gkbophthalmics@gkb.net
Website : www.gkb.net

August 13, 2024

Department of Corporate Services
BSE Limited
Phiroze Jeejubhoy Towers, Dalal Street
Mumbai - 400 001

Dear Sir,

Ref : Scrip Code No. : 533212

Sub : Outcome of Board Meeting of GKB Ophthalmics Limited held on August 13, 2024.

The meeting of the Board of Directors of the Company was held on August 13, 2024, which considered and took on record the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2024.

Pursuant to Regulation 33 (3) (d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, enclosed please find the following:

1. Standalone Financial Results for the quarter ended June 30, 2024, together with the Limited Review Report
2. Consolidated Financial Results for the quarter ended June 30, 2024, together with Limited Review Report.

The above Unaudited Financial Results and the Limited Review Reports are available on the Company's website www.gkb.net and on the BSE website www.bseindia.com

3. The Board of Directors in its meeting held on May 30, 2024, had directed to change the accounting policy with effect from April 1, 2024 to treat glass moulds as inventory and charge only the actual utilisation of the glass moulds in the manufacturing process which would result in an adequate charge to consumption in the Statement of Profit & Loss. Post the Board Meeting, the management internally reviewed the entire situation and came to a conclusion that moulds which are being used in the production process are currently being used for more than one accounting period from the date of put to use. This characteristic of mould fits in the definition of IND AS 16- 'Property, Plant and Equipment.' The Board of Directors deliberated upon the same and decided to withdraw its stand of changing the accounting policy with effect from April 01, 2024 of treating glass moulds as inventory. The Board of Directors agreed to reinstate the earlier accounting policy of treating glass moulds as Property, Plant and Equipment. Hence, there would be no change in the Accounting Policy in the Financial Year 2024-25.

The Board of Directors' Meeting started at 04.30 P.M. and ended at 06:25 P.M., on the same day.

Kindly take the information on record.

Thanking you,

Yours faithfully,
For GKB Ophthalmics Ltd.,

Pooja Bicholkar
Company Secretary



Independent Auditor's Review Report on Standalone unaudited financial results of GKB Ophthalmics Limited for the quarter ended June 30, 2024 pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To The Board of Directors of GKB Ophthalmics Limited

1. We have reviewed the accompanying statement of standalone unaudited financial results of GKB Ophthalmics Limited (hereinafter referred to as 'the Company') for the quarter ended June 30, 2024 ('the Statement') attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the Regulations').
2. This Statement, which is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting', prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with relevant rules issued thereunder ('Ind AS 34') and other recognised accounting principles generally accepted in India and is in compliance with the Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 and other recognised accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For M S K A & Associates
Chartered Accountants
ICAI Firm Registration No. 105047W

Manohar Juman
Nft. Manohar Juman
Partner
Membership No.: 111700
UDIN: 24111700BKAIMY8310



Place: Pune
Date: August 13, 2024

**GKB Ophthalmics Limited**

CIN : L26109GA1981PLC000469

Regd. Office: 16-A, Tivim Industrial Estate, Mapusa Goa. 403 526

Tel No. (0832) 6714444 E-mail: gkbophthalmics@gkb.net Website: www.gkb.net

Statement of Unaudited Standalone Financial Results for the Quarter ended June 30, 2024

(Rs. In Lakhs except earnings per share data)

	Particulars	Quarter ended			Year Ended
		June 30, 2024 (Unaudited)	March 31, 2024 (Refer Note 4)	June 30, 2023 (Unaudited)	Mar 31, 2024 (Audited)
	Income:				
1	Revenue from operations	861.90	735.66	970.97	3,118.05
2	Other income	8.93	19.51	9.15	207.74
3	Total income (1+2)	870.83	755.17	980.12	3,325.79
4	Expenses:				
	a) Cost of materials consumed	487.22	335.33	490.99	1,639.74
	b) Purchases of stock -in-trade	1.76	2.94	-	6.39
	c) Changes in inventories of finished goods and work-in-progress	(14.03)	44.19	4.70	25.54
	d) Employee benefits expense	266.59	265.90	198.12	921.67
	e) Finance costs	41.08	48.22	37.17	159.33
	f) Depreciation and amortisation expense	65.00	64.03	63.65	258.60
	g) Other expenses	162.94	128.03	177.91	652.14
	Total expenses	1,010.56	888.64	972.54	3,663.41
5	Profit / (Loss) before tax (3-4)	(139.73)	(133.47)	7.58	(337.62)
6	Tax expenses				
	a) Current Tax	-	-	-	-
	b) Deferred Tax	1.00	3.86	0.05	4.02
7	Profit / (Loss) for the periods / year (5-6)	(140.73)	(137.33)	7.53	(341.64)
8	Other comprehensive income:				
	Items that will not be reclassified to profit or loss				
	Remeasurement of net defined benefit liability	(3.86)	(14.83)	(0.21)	(15.45)
	Income tax effect	1.00	3.86	0.05	4.02
	Other comprehensive income / (loss) for the periods / year	(2.86)	(10.97)	(0.16)	(11.43)
9	Total Comprehensive income / (loss) for the periods / year (7+8)	(143.59)	(148.30)	7.37	(353.07)
10	Paid-up equity share capital (face value of share - Rs. 10 each fully paid up)	504.06	504.06	504.06	504.06
11	Reserves excluding revaluation reserve				1,894.51
12	Earnings Per Share (face value of Rs. 10 each)				
	(a) Basic (in Rs.)	(2.80)	(2.73)	0.15	(6.78)
	(b) Diluted (in Rs.)	(2.80)	(2.73)	0.15	(6.78)
	* Not Annualised	*	*	*	*

See accompanying notes




GKB Ophthalmics Limited
CIN : L26109GA1981PLC000469

- 1 The above unaudited standalone financial results for the quarter ended June 30, 2024 have been subjected to limited review by the statutory auditors of the Company and reviewed by the Audit Committee and approved by the Board of Directors of the Company at the meeting held on August 13, 2024.
- 2 The utilisation / status of funds raised from preferential issue by the Company is as follows :-

Particulars	As at June 30, 2024 (Rs. In lakhs)	As at March 31, 2024 (Rs. In lakhs)
Towards funding growth plans - organic and inorganic	1,170.00	1,170.00
Towards scaling up of operations, long term capital requirements and other general corporate purpose	342.27	335.05
Total funds utilised (A)	1,512.27	1,505.05
Unutilised amount lying in Escrow account (B)	-	7.22
Total funds raised (A + B)	1,512.27	1,512.27

- 3 The Company is engaged in manufacturing of ophthalmic lenses. The chief operating decision maker (CODM) reviews the operations of the Company as a one single operating business segment. Hence, no separate reportable business segments have been identified for disclosure.
- 4 The figures for the quarter ended March 31, 2024 are balancing figures between the audited figures in respect of the full financial year and the published unaudited year to date figures upto the third quarter of the financial year.

For and on behalf of the Board of Directors
of GKB Ophthalmics Limited



K. G. Gupta
Managing Director
DIN : 00051863



Place : Mapusa - Goa
Date : August 13, 2024



Independent Auditor's Review Report on consolidated unaudited financial results of GKB Ophthalmics Limited for the quarter ended June 30, 2024 pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of GKB Ophthalmics Limited

1. We have reviewed the accompanying Statement of consolidated unaudited financial results of GKB Ophthalmics Limited (hereinafter referred to as 'the Holding Company'), its subsidiaries, (the Holding Company and its subsidiaries together referred to as the 'Group') and its share of the net profit after tax and total comprehensive income of its associate for the quarter ended June 30, 2024 ('the Statement'), attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the Regulations').
2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting' prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with relevant rules issued thereunder ('Ind AS 34') and other recognised accounting principles generally accepted in India and is in compliance with the Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33 (8) of the Regulations, to the extent applicable.

4. This Statement includes the results of the Holding Company and the following entities:

Sr. No	Name of the Entity	Relationship with the Holding Company
i.	GSV Ophthalmics Private Limited	Subsidiary
ii.	GKB Ophthalmics Products [FZE]	Wholly Owned Subsidiary
iii.	Lensco - The lens company	Step Down Subsidiary
iv.	Prescription Optical Products LLC	Step Down Subsidiary
v.	GKB Vision FZC	Associate

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of other auditors referred to in paragraph 6, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 and other recognised accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.



MSKA & Associates

Chartered Accountants

6. We did not review the interim financial information of two subsidiaries and one step-down subsidiary included in the Statement, whose interim financial information reflect total revenues of Rs. 1,959.53 lakhs, total net profit after tax and total comprehensive income of Rs. 128.23 lakhs for the quarter ended June 30, 2024, as considered in the Statement. These interim financial information have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries and step-down subsidiary, is based solely on the report of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion is not modified in respect of the above matter with respect to our reliance on the work done by and report of the other auditors.

7. The Statement includes the interim financial information of one step-down subsidiary which has not been reviewed by its auditors, whose interim financial information reflects total revenue of Rs. 65.95 lakhs, total net profit after tax and total comprehensive income of Rs. 7.06 lakhs for the quarter ended June 30, 2024, as considered in the Statement. The Statement also includes the Group's share of net profit after tax of Rs. 14.72 lakhs for the quarter ended June 30, 2024, as considered in the Statement, in respect of an associate, based on its interim financial information which has not been reviewed by its auditor. These interim financial information have been furnished to us by the Management and our conclusion on the Statement in so far as it relates to the amounts and disclosures included in respect of the step-down subsidiary and an associate is based solely on such Management prepared unaudited interim financial information. According to the information and explanations given to us by the Management, these interim financial information are not material to the Group.

Our conclusion is not modified in respect of the above matter with respect to our reliance on the financial result certified by the management.

For M S K A & Associates
Chartered Accountants
ICAI Firm Registration No.105047W


Nitin Manohar Jyani
Partner

Membership No.: 111700

UDIN: 24111700BKAIMZ2940



Place: Pune

Date: August 13, 2024



GKB Ophthalmics Limited

CIN : L26109GA1981PLC000469

Regd. Office: 16-A, Tivim Industrial Estate, Mapusa Goa. 403 526


Tel No. (0832) 6714444 E-mail: gkbophthalmics@gkb.net Website: www.gkb.net

Statement of Unaudited Consolidated Financial Results for the Quarter ended June 30, 2024

(Rs. In Lakhs except earnings per share data)

	Particulars	Quarter Ended			Year Ended
		June 30, 2024	March 31, 2024	June 30, 2023	March 31, 2024
		(Unaudited)	(Refer Note 5)	(Unaudited)	(Audited)
	Income:				
1	Revenue from operations	2,601.76	2,155.76	2,225.82	8,825.40
2	Other income	28.13	49.78	34.97	150.56
3	Total Income (1+2)	2,629.89	2,205.54	2,260.79	8,975.96
	Expenses:				
4	a) Cost of materials consumed	513.97	338.40	499.52	1,504.53
	b) Purchases of stock in trade	1,224.98	1,263.66	1,042.09	4,708.85
	c) Changes in inventories of finished goods, stock in trade and work-in-progress	(12.40)	(160.03)	(83.92)	(239.60)
	d) Employee benefits expense	403.58	376.71	299.56	1,375.83
	e) Finance costs	55.34	57.36	43.47	190.33
	f) Depreciation and amortisation expense	75.56	71.68	71.56	289.87
	g) Other expenses	367.52	336.44	333.04	1,417.88
	Total expenses	2,628.55	2,284.22	2,205.32	9,247.69
5	Profit / (Loss) before share of profit / (loss) of an associate and tax (3-4)	1.34	(78.68)	55.47	(271.73)
6	Share in profit / (loss) of an associate	14.72	9.74	(1.00)	(5.86)
7	Profit/(loss) before tax (5+6)	16.06	(68.94)	54.47	(277.59)
8	Tax expenses				
	a) Current Tax	4.56	18.81	-	18.81
	b) Prior Period Tax	-	(2.21)	-	(2.21)
	c) Deferred Tax	1.00	3.86	0.05	4.02
9	Profit / (loss) for the periods / year (7-8)	10.50	(89.40)	54.42	(298.21)
10	Other comprehensive Income :-				
	Items that will not be reclassified to profit or loss				
	Remeasurement of net defined benefit liability	(3.86)	(14.83)	(0.21)	(15.45)
	Income tax effect	1.00	3.86	0.05	4.02
	Other comprehensive Income / (loss) for the periods / year	(2.86)	(10.97)	(0.16)	(11.43)
11	Total Comprehensive income / (loss) for the periods / year (9+10)	7.64	(100.37)	54.26	(309.64)
12	Profit / (Loss) for the period / year attributable to				
	Equity holders of the parent	(25.37)	(91.41)	52.39	(281.05)
	Non-controlling interest	35.87	2.01	2.03	(17.16)
	Total	10.50	(89.40)	54.42	(298.21)
	Other comprehensive income / (loss) for the periods / year attributable to				
	Equity holders of the parent	(2.86)	(10.97)	(0.16)	(11.43)
	Non-controlling interest	-	-	-	-
	Total	(2.86)	(10.97)	(0.16)	(11.43)
	Total Comprehensive income / (loss) for the periods / year attributable to				
	Equity holders of the parent	(28.23)	(102.38)	52.23	(292.48)
	Non-controlling interest	35.87	2.01	2.03	(17.16)
	Total	7.64	(100.37)	54.26	(309.64)
13	Paid-up equity share capital (face value of share - Rs. 10 each)	504.06	504.06	504.06	504.06
14	Reserves excluding revaluation reserve				5,473.06
15	Earnings Per Share (face value of Rs. 10 each)				
	(a) Basic (In Rs.)	(0.50)	(1.81)	1.04	(5.58)
	(b) Diluted (In Rs.)	(0.50)	(1.81)	1.04	(5.58)
	* Not Annualised	*	*	*	*

See accompanying notes





1 The unaudited consolidated financial results include results of the following companies:

Name of the Company	Relationship
1. GKB Ophthalmics Limited	Holding Company
2. GSV Ophthalmics Private Limited	Subsidiary
3. GKB Ophthalmics Products [FZE]	Wholly Owned Subsidiary
(Including its following Subsidiaries and Associate)	
a. Lensco - The lens company (Subsidiary)	
b. Prescription Optical Products LLC (Subsidiary)	
c. GKB Vision FZC (Associate - 49% Holding)	

The Holding Company together with the subsidiaries are referred to as the Group

2 The above unaudited consolidated financial results for the quarter ended June 30, 2024 have been subjected to limited review by the statutory auditors of the Holding Company and reviewed by the Audit Committee and approved by the Board of Directors of the Holding Company at the meeting held on August 13, 2024.


3 The utilisation / status of funds raised from preferential issue by the Holding Company is as follows :-


Particulars	As at June 30, 2024 (Rs. In lakhs)	As at March 31, 2024 (Rs. In lakhs)
Towards funding growth plans - organic and inorganic	1,170.00	1,170.00
Towards scaling up of operations, long term capital requirements and other general corporate	342.27	335.05
Total funds utilised (A)	1,512.27	1,505.05
Unutilised amount lying in Escrow account (B)	-	7.22
Total funds raised (A + B)	1,512.27	1,512.27

4 The Group is engaged in manufacturing of ophthalmic lenses. The chief operating decision maker (CODM) reviews the operations of the Company as a one single operating business segment. Hence, no separate reportable business segments have been identified for disclosure.

5 The figures for the quarter ended March 31, 2024 are balancing figures between the audited figures in respect of the full financial year and the published unaudited year to date figures upto the third quarter of the financial year.

For and on behalf of the Board of Directors
of GKB Ophthalmics Limited


K. G. Gupta
Managing Director
DIN : 00051863



Place : Mapusa - Goa
Date : August 13, 2024

